On 24th December 2020, the EU and UK agreed a post-Brexit free trade agreement (FTA), just in the nick of time before the UK exited EU trading rules on 31 December 2020.
I’ve been guilty of foot drag myself up to this point, figuring a) we might not leave in the end (cue hollow laugh), b) until the FTA detail was known, not much point in doing anything, and c) in the absence of a legal framework, the fall back would be in the direction of ICH, which my clients already aspire to comply with.
But now the deal has been done, and so the time has come to start engaging with those pesky details. In the next few days and weeks, I am going to take a deep dive into the publications, with the intention of capturing key points in this blog on any implications, primarily for clinical trial conduct and GCP. This will be a personal interpretation, so don’t take my word as gospel – I will always provide links to the primary publication so you can check it out for yourself.
Please use the comments section to let me know if you agree with my assessments, and to draw my attention to any other publications which warrant further scrutiny.